Home / Market News / $REGN
benzinga Corporate Catalyst Impact 55/100 ● positive

Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $865

Oct 19, 2026, 4:23 PM UTC · Primary ticker $REGN

Piper Sandler analyst Biren Amin maintained an Overweight rating on Regeneron Pharmaceuticals and increased the price target from $854 to $865. This indicates continued analyst confidence in the company's future performance, potentially leading to a modest positive sentiment for the stock.

Piper Sandler's analyst Biren Amin reiterated an 'Overweight' rating on Regeneron Pharmaceuticals (REGN) and slightly raised the price target from $854 to $865. This action signals continued bullish sentiment from a prominent investment bank regarding REGN's prospects. For traders, this provides a short-term positive signal, potentially leading to a modest uptick in share price as investors react to the updated target. While not a major catalyst like an earnings beat or drug approval, it reinforces existing positive narratives around the company. The long-term implication is a sustained positive outlook, though the impact of a minor price target adjustment is generally limited.

$REGN positive Price target increase and maintained Overweight rating
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.